Leland Stanford Junior University

The United States Government As Represented by the Department of Veterans Affairs

Other

Sri International

Alkahest, Inc.

University of California

Satoris, Inc.

Anton Wyss-Coray

Saul A Villeda

Jian Luo

Thomas A Rando

Mary Jean Tanga

Markus Britschgi

Kaspar Rufibach

Joseph M Castellano

Sandip Ray

Carolyn Ruth Bertozzi

Benjamin J Smith

Steven P Braithwaite

Hui Zhang

Martin S Angst

Karoly Nikolich

Hanadie Yousef

Michael C Bassik

Hilal Lashuel

Carol Green

Laura Ellen Downs Beaulieu

Vidhu Mathur

Ritwik Burai

John Vincent Pluvinage

Kyle Brewer

Andrew Yang

Michael Haney

Jinte Middeldorp

Andrew Chris Yang

Provided herein are methods for labeling the proteomes of cells, as well as methods for labeling proteins or populations of proteins produced by cells. In some embodiments, the methods comprise introducing variant aminoacyl-tRNA synthetases and noncanonical amino acids into cells. Also provided herein are polynucleotides encoding variant aminoacyl-tRNA synthetases that recognize noncanonical amino acids. The methods and compositions provided herein are useful for, among other things, identifying target cells and identifying biomarkers of interest.

Methods for proteome labeling

Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

Method of treating aging-associated cognitive impairment by reducing CCR3

Provided herein are compositions, methods, kits and systems for treating cells, tissues and subjects to alter age-related biology (e.g., to study or to treat age-related diseases and conditions). In particular, provided herein are compositions, methods, and uses for inhibition or modification of sialic acid or its cognate receptor to restore phagocytosis in aged cells.

Compositions and methods for treating age-related diseases

Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)

Methods of treating an adult mammal for an aging-associated condition are provided. Aspects of the methods include enhancing a TIMP activity, e.g., a TIMP2 activity, in the mammal in a manner sufficient to treat the adult mammal for the aging-associated condition. Also provided are compositions for use in practicing methods of the invention. A variety of aging-associated conditions may be treated by practice of the methods, which conditions include cognitive impairments.

Methods and compositions for treating aging-associated conditions

Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing cell surface VCAM-1 activity in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

VCAM-1 mediated methods and compositions for treating aging-associated impairments

Methods and compositions are provided for screening candidate compositions for activity with respect to treatment of aging-associated conditions, e.g., cognitive impairment conditions or age-related dementia. Aspects of the methods include administering a human blood product comprising plasma, to an immunocompromised animal, e.g., a mouse or a rat, and measuring the effect of the product on an endpoint, e.g., neurogenesis, locomotor activity, anxiety, spatial memory, and hippocampus-dependent memory.

Methods for screening human blood products comprising plasma using immunocompromised rodent models

Methods and compositions are provided for treating a subject for aging-associated conditions, e.g., cognitive impairment conditions. Aspects of the methods include administering a young plasma-comprising blood product to an individual in need thereof, e.g., an individual suffering from or at risk of developing the aging-associated condition, e.g., aging-associated cognitive impairment. Also provided are compositions and kits thereof that find use in practicing methods of the invention.

The present invention provides methods for preventing, attenuating neuronal damage or stimulating neuronal repair prior or following central nervous system injury.

Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists

Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)

Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the 2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

Methods and compositions for treating aging-associated impairments

Compositions and methods for modulating innate and adaptive immunity and for use in immunotherapy are disclosed. In particular, the invention relates to novel ganciclovir derivatives and methods of using them for the treatment of immune-related disorders, including inflammation, autoimmunity, and infections, and neurological disorders, and cancer.

Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy

Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-B signaling are described. In particular, the compositions and methods are useful for reducing or eliminating the pathologies associated with Alzheimer's disease. The compositions include urea derivatives containing a piperidine, piperidinium, or a piperidin-4-yl methyl; cycloalkyl, aryl, and fluorobenzyl moieties.

Benzyl urea derivatives for activating TGF-beta signaling

Disclosed are novel methods for preventing or attenuating neuronal damage or stimulating neuronal repair, prior to or following central nervous system injury associated with acute or chronic nervous system injury. Macrophage colony stimulating factor receptor agonists including macrophage colony stimulating factor (M-CSF or CSF-1), interleukin-34 (IL-34), proteins or biologically active fragments thereof, peptides or biologically active fragments thereof, peptidomimetics, or small molecules, and the like are effective for prevention or treatment of acute nervous system injury or chronic nervous system injury involving Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and the like.

Growing community of inventors

Palo Alto, CA, United States of America

Anton Wyss-Coray